64852 Federal Register / Vol. 62, No. 236 / Tuesday, December 9, 1997 / Notices

within two days prior to discharge from

an inpatient facility to home.

3. The most recent arterial blood gas

PO2 and/or oxygen saturation test

performed at rest, during exercise, or

during sleep.

4. Name and address of the physician/

provider performing the most recent

arterial blood gas PO2 and/or oxygen

saturation test.

5. If ordering portable oxygen,

information regarding the patient’s

mobility within the home.

6. Identification of the highest oxygen

flow rate (in liters per minute)

prescribed.

7. If the prescribed liters per minute

(LPM), as identified in item 6, are

greater than 4 LPM, provide the results

and date of the most recent arterial

blood gas PO2 and/or oxygen saturation

test taken on 4 LPM.

If the PO2 = 56–59, or the oxygen

saturation = 89%, then evidence of the

beneficiary meeting at least one of the

following criteria must be provided.

8. The patient having dependent

edema due to congestive heart failure.

9. The patient having cor pulmonale

or pulmonary hypertension, as

documented by P pulmonale on an EKG

or by an echocardiogram, gated blood

pool scan or direct pulmonary artery

pressure measurement.

10. The patient having a hematocrit

greater than 56%.

Form HCFA–484 obtains all pertinent

information and promotes national

consistency in coverage determinations;

Frequency: Other (as needed); Affected

Public: Individuals/households,

business or other for profit, and not for

profit institutions; Number of

Respondents: 300,000; Total Annual

Responses: 300,000; Total Annual

Hours Requested: 50,000.

To obtain copies of the supporting

statement, and any related forms

referenced above, E-mail your request,

including your address and phone

number, to Paperwork@hcfa.gov, or call

the Reports Clearance Office on (410)

786–1326. Written comments and

recommendations for the proposed

information collections must be mailed

within 30 days of this notice directly to

the OMB Desk Officer designated at the

following address: OMB Human

Resources and Housing Branch,

Attention: Allison Eydt, New Executive

Office Building, Room 10235,

Washington, D.C. 20503.

Dated: December 2, 1997.

John P. Burke III,

HCFA Reports Clearance Officer, HCFA,

Office of Information Services, Information

Technology Investment Management Group,

Division of HCFA Enterprise Standards.

[FR Doc. 97–32100 Filed 12–8–97; 8:45 am]

BILLING CODE 4120–03–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of

National Cancer Institute Director’s

Consumer Liaison Group Meeting

Notice is hereby given that the

National Cancer Institute will hold its

first public meeting of the Director’s

Consumer Liaison Group, beginning at

9:00 a.m. on December 17, 1997 and

ending at 3:00 p.m. on December 18,

1997 at the Pooks Hill Marriott,

Bethesda, MD. Seating is limited and

will be on a first-come, first-served

basis.

The National Cancer Institute (NCI),

the federal government’s primary

agency for cancer research, is bringing

together fifteen (15) consumer-advocates

to create a two-way street that enables

them to interact directly with the

scientific community at NCI on a wide

range of programs and issues. The 15-

member DCLG is made up of people

involved in cancer advocacy and who

reflect the breadth and diversity among

those whose lives are touched by

cancer. The DCLG will also help NCI to

widen the pool of qualified consumeradvocates who can be called upon to

serve on NCI advisory committees and

other groups.

The members are (in alphabetical

order):

Paula E. Bowen, Brooklyn, N.Y.

Susan Lowell Butler, Alexandria, Va.

Manuel H. Castillo, Dayton, Ohio

Kerry J. Dewey, Missoula, Mont.

M. Venus Gines, Lithonia, Ga.

Felicia Schanche Hodge, Berkeley, Calif.

Michael Katz, New York, N.Y.

Susan A. Leigh, Tucson, Ariz.

Ruth Chiang Lin, Short Hills, N.J.

Gena H. Love, Albuquerque, N.M.

Susan McCarthy, Vancouver, Wash.

Daniel M. Moore, Jr., Decatur, Ill.

Lillouise Rogers, Chicago, Ill.

Susan K. Stewart, Highland Park, Ill.

Brad Zebrack, Ann Arbor, Mich.

The majority of the newly appointed

DCLG members are cancer survivors,

but family members of cancer patients

and health professionals involved in

cancer advocacy are represented. The

cancer experience of the group includes

prostate, breast, kidney, ovarian,

cervical, lung, bladder, and brain

cancer, Hodgkin’s disease, leukemia,

sarcoma, and myeloma. The group

represents Asian American, Native

American, Hispanic, African American,

and non-Hispanic white persons, the

young and old, men and women, the

medically underserved, and people from

all geographic areas of the country, both

rural and urban. The constituencies

represented by the members include

advocacy organizations that represent

both specific cancers and all cancers.

DCLG members will serve three-year

terms. The three-fold purpose of the

DCLG will be to:

• Serve as a primary forum for

discussing issues and concerns and

exchanging viewpoints that are

important to the broad development of

NCI program and research priorities.

• Help develop and establish

processes, mechanisms, and criteria for

identifying appropriate consumer

advocates to serve on a variety of NCI

program and policy advisory

committees.

• Establish and maintain strong

collaborations between NCI and the

cancer advocacy community.

One purpose of this first meeting is to

decide how the group will do its work.

For example, how it will select a chair

and identify members who will serve in

the future. The DCLG will also discuss

how it will communicate internally and

with the broad advocacy community it

represents. In addition, the group will

begin discussion on several key issues

for the Institute. The most pressing

issues faced by cancer patients today, as

described in the candidates’

applications, include: Access to and

availability of reliable cancer

information; access to effective, highquality treatment, including clinical

trials; increased rehabilitation,

psychosocial support, and other

survivor concerns; and participation in

setting research priorities. NCI may also

begin issues to the attention of the

group.

Individuals who plan to attend the

meeting and need special assistance,

such as sign language interpretation or

other special accommodations, should

contact Elaine C. Lee, in the Office of

Liaison Activities, National Cancer

Institute, Building 31, Room 10A06; or

by calling telephone No. 301 594–3194

or sending a fax to 301 480–7558. For

additional information, contact Ms. Lee

at the above address.
Federal Register / Vol. 62, No. 236 / Tuesday, December 9, 1997 / Notices 64853

Dated: December 2, 1997.

Marvin Kalt,

Director, Division of Extramural Activities,

National Cancer Institute.

[FR Doc. 97–32089 Filed 12–8–97; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of

Closed Meeting

Pursuant to Section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

National Cancer Institute Special

Emphasis Panel (SEP) meeting:

Name of SEP: SBIR Phase I—Innovative

Approaches to Clinical Trials 1 Informatics

(Telephone Conference Call).

Date: December 15, 1997.

Time: 2:30 p.m. to Adjournment.

Place: National Cancer Institute, Executive

Plaza North, Conference Room 640, 6130

Executive Boulevard, Bethesda, MD 20892.

Contact Person: Wilna Woods, Ph.D.,

Scientific Review Administrator, National

Cancer Institute, NIH, Executive Plaza North,

Room 622B, 6130 Executive Boulevard, MSC

7405, Bethesda, MD 20892–7405, Telephone:

301/496–7903.

Purpose/Agenda: To review, discuss and

evaluate responses to Request for Proposal.

This notice is being published less than 15

days prior to the meeting due to the urgent

need to meet timing limitations imposed by

the review and funding cycle.

The meeting will be closed in accordance

with the provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5, U.S.C.

Proposals and the discussions could reveal

confidential trade secrets or commercial

property such as patentable material and

personal information concerning individuals

associated with the proposals, the disclosure

of which would constitute a clearly

unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance

Program Numbers: 93.393, Cancer Cause and

Prevention Research; 93.394, Cancer

Detection and Diagnosis Research; 93.395,

Cancer Treatment Research; 93.396, Cancer

Biology Research; 93.397, Cancer Centers

Support; 93.398, Cancer Research Manpower;

93.399, Cancer Control)

Dated: December 2, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97–32090 Filed 12–8–97; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Institute of Allergy and

Infectious Diseases; Notice of Closed

Meeting

Pursuant to Section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

National Institute of Allergy and

Infectious Diseases Special Emphasis

Panel (SEP) meeting:

Name of SEP: Unsolicited R01 (Telephone

Conference Call).

Date: December 16, 1997.

Time: 12:00 p.m. to Adjournment.

Place: Teleconference, 6003 Executive

Boulevard, Solar Building, Room 4C01,

Bethesda, MD 20892, (301) 496–2550.

Contact Person: Dr. Dennis Lang, Scientific

Review Adm., 6003 Executive Boulevard,

Solar Bldg., Room 4C16, Bethesda, MD

20892, (301) 496–2550.

Purpose/Agenda: To evaluate a grant

application.

The meeting will be closed in accordance

with the provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5, U.S.C.

Applications and/or proposals and the

discussions could reveal confidential trade

secrets or commercial property such as

patentable material and personal information

concerning individuals associated with the

applications and/or proposals, the disclosure

of which would constitute a clearly

unwarranted invasion of personal privacy.

This notice is being published less than 15

days prior to the meeting due to the urgent

need to meet timing limitations imposed by

the review and funding cycle.

Dated: December 2, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97–32087 Filed 12–8–97; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Institute on Drug Abuse;

Notice of Closed Meetings

Pursuant to Section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

National Institute on Drug Abuse

(NIDA) Special Emphasis Panel

meetings.

Purpose/Agenda: To review and evaluate

grant applications and contract proposals.

Name of Committee: NIDA Special

Emphasis Panel (Contract Review—‘‘InternetBased Research Support for Drug Abuse

Researchers’’).

Date: December 10, 1997.

Time: 9:00 a.m.

Place: Bethesda Marriott Hotel, 5151 Pooks

Hill Road, Bethesda, MD 20814.

Contact Person: Mr. Lyle Furr, Contract

Review Specialist, Office of Extramural

Program Review, National Institute on Drug

Abuse, 5600 Fishers Lane, Room 10–42,

Rockville, MD 20857, Telephone (301) 443–

1644.

Name of Committee: NIDA Special

Emphasis Panel (Contract Review—

‘‘Development of a Computerized

Neuropsychological Testing Programs’’).

Date: December 17, 1997.

Time: 9:00 a.m.

Place: Bethesda Marriott Hotel, 5151 Pooks

Hill Road, Bethesda, MD 20814.

Contact Person: Mr. Lyle Furr, Contract

Review Specialist, Office of Extramural

Program Review, National Institute on Drug

Abuse, 5600 Fishers Lane, Room 10–42,

Rockville, MD 20857, Telephone (301) 443–

1644.

Name of Committee: NIDA Special

Emphasis Panel (Contract Review)—

‘‘Analytical Techniques Programs’’).

Date: December 19, 1997.

Time: 11:30 a.m.

Place: National Institute on Drug Abuse,

NIH, 5600 Fishers Lane, Room 10–49,

Rockville, MD 20857.

Contact Person: Mr. Eric Zatman, Contract

Review Specialist, Office of Extramural

Program Review, National Institute on Drug

Abuse, 5600 Fishers Lane, Room 10–42,

Rockville, MD 20857, Telephone (301) 443–

1644.

This notice is being published less than 15

days prior to the meetings due to the urgent

need to meet timing limitations imposed by

the review and funding cycle.

Name of Committee: NIDA Special

Emphasis Panel (Contract Review—‘‘Develop

Prevention Research Dissemination’’).

Date: January 7, 1998.

Time: 9:00 a.m.

Place: Bethesda Marriott Hotel, 5151 Pooks

Hill Road, Bethesda, MD 20814.

Contact Person: Mr. Lyle Furr, Office of

Extramural Program Review, National

Institute on Drug Abuse, 5600 Fishers Lane,

Room 10–42, Rockville, MD 20857,

Telephone (301) 443–1644.

Name of Committee: NIDA Special

Emphasis Panel (Conference Grants).

Date: January 8, 1998.

Time: 9:00 a.m.

Place: National Institute on Drug Abuse,

NIH, NIDA Conference Room 10–05, 5600

Fishers Lane, Rockville, MD 20857.

Contact Person: Dr. William C. Grace,

Scientific Review Administrator, Office of

Extramural Program Review, National

Institute on Drug Abuse, 5600 Fishers Lane,

Room 10–42, Rockville, MD 20857,

Telephone (301) 443–2755.

The meetings will be closed in accordance

with provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5, U.S.C. The

applications and/or proposals and the

discussions could reveal confidential trade

secrets or commercial property such as

patentable material and personal information

concerning individuals associated with the